While the HPV vaccine is still widely associated with preventing cervical cancer in women, a growing body of evidence shows it also prevents cancer in men — even as awareness of this benefit lags, particularly among the remarkably groups most at risk.
In Canada, a new survey from Merck reveals that nearly half of men do not realize what HPV is or what health consequences it can carry, even as throat cancer — now the most common HPV-related malignancy in the country — continues to rise among males. Only 47% of men surveyed recognized their role in preventing transmission, compared to 74% of women. Among young adults aged 18 to 24, just 49% identified HPV as a sexually transmitted infection and a third admitted they had never heard of it.
This gap in understanding persists despite clear epidemiological shifts. While cervical cancer remains a significant concern globally, oropharyngeal cancer has surpassed it as the leading HPV-associated cancer in Canada, disproportionately affecting men. Yet, 53% of all respondents — across age and gender — were unaware that rates of these head and neck cancers are increasing among males. The disconnect between rising disease burden and public knowledge creates a preventable burden, especially as the virus spreads silently through populations with limited screening options for males.
In India, where cervical cancer claims nearly 80,000 lives annually, pediatrician Dr. Tarlochan Singh Randhawa emphasized that men are often silent carriers of HPV, with no equivalent to the Pap smear for early detection. He noted that the vaccine — which he described as 85 to 97% effective — remains the only reliable preventive strategy for males, protecting against penile cancer, genital warts, and head and neck neoplasms. He urged state authorities to expand education efforts beyond girls, warning that misinformation about vaccine safety continues to undermine uptake.
These concerns are met with strong counter-evidence from a large international cohort study published in JAMA Oncology. Analyzing data from over 2.9 million males aged 9 to 26 between 2016 and 2024, researchers found that those who received at least one dose of the 9-valent HPV vaccine had a 46% lower risk of developing any HPV-related cancer compared to unvaccinated peers. The protective effect held across age groups: a 42% reduction among boys aged 9 to 14 and a 50% reduction in those aged 15 to 26. After adjusting for confounding variables through propensity score matching, the study compared 510,260 vaccinated and unvaccinated individuals, strengthening the validity of its findings.
For more on this story, see HPV Vaccine Prevents Cancer in Men and Boys, Study Finds.
The data underscore a growing consensus: vaccinating boys is not merely an extension of a female-focused program but a direct intervention with measurable impact on male health. Yet, as the Canadian survey shows, the message is not reaching those who necessitate it most. Nearly three-quarters of respondents cited barriers to discussing HPV with healthcare providers — ranging from simple lack of information to embarrassment — suggesting that clinical encounters remain underutilized opportunities for education.
Efforts to close this gap face cultural and structural headwinds. In many regions, HPV vaccination is still framed through the lens of cervical cancer prevention, inadvertently signaling that the vaccine is not relevant to males. This perception persists even as epidemiological data show that men now bear a disproportionate share of the HPV-related cancer burden in several high-income countries. The result is a feedback loop: low awareness leads to low uptake, which sustains transmission and disease, which in turn reinforces the perception that HPV is a “women’s issue.”
Breaking this cycle requires more than just expanding eligibility. It demands a reframing of public health messaging — one that speaks directly to men about their own risk, their role in transmission, and the tangible protection the vaccine offers. As Dr. Randhawa pointed out, without accessible screening for males, vaccination becomes not just beneficial but essential. The science is clear: the vaccine works. The challenge now is ensuring that the people who stand to benefit most are the ones who know it.
This follows our earlier report, Woman Develops Multiple Cancers After Husband Cheated and Gave Her HPV.
Why is HPV vaccination still seen as primarily for girls?
Because public health campaigns and medical screening have long focused on cervical cancer prevention, creating a perception that the virus and its vaccine are mainly relevant to females, despite evidence showing men face significant risks from HPV-linked cancers like throat and penile cancer.
How effective is the HPV vaccine in preventing cancer in boys?
According to a large international study, boys who received at least one dose of the 9-valent HPV vaccine had a 46% lower risk of developing HPV-related cancers compared to unvaccinated peers, with protection ranging from 42% in younger adolescents to 50% in older teens and young adults.
What barriers prevent people from learning about HPV?
Surveys show that nearly three-quarters of respondents cite obstacles such as lack of information, embarrassment, or discomfort when trying to discuss HPV with healthcare providers, limiting opportunities for education and clarification.
Worth a look
